contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nordhealth-oy-nordhealth-as-amendment-of-performance-based-options-to-executive-management-and-key-employees

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NordHealth operates in the technology industry. The company specializes in developing software for digital health. The software is developed in-house and is mainly used in the healthcare sector. Customers consist of corporate customers operating in various sectors such as hospitals, clinics, veterinarians. In addition to the main business, various value-added services are also offered. The largest operations are found in the Nordic region.

Interesting company and interesting industry  Some comments:  About 95% of revenue came from the Nordic countries in 2020. This was before the Aspit acquisition, so even more after this acquisition. At the same time, the company’s market share in Finland, Sweden, and Norway in the veterinary sector is already 80-95%. In Denmark, it’s about 30%. While the market is growing, this means it’s difficult to maintain historical organic growth rates because, simply put, there aren’t as many potential clinics in the Nordics that can be added as customers. Of course, high net retention will likely ensure 15-20% YoY growth even without new customers, plus perhaps another 5% from new clinics. If we compare this to Carasent (not a direct competitor, but healthcare SaaS), the net retention is roughly the same, but in Cara’s case, new clinics should provide an additional 20-30% growth YoY. Therefore, to even get close to historical organic growth, they would need to succeed really well in the US. This is certainly possible. Firstly, IDEXX recently acquired ezyVet, and secondly, Pathway acquired Vetspire, and both deals are likely to benefit Nordhealth in the long run. Why? IDEXX and Pathway are large organizations, and neither of the acquired companies will receive the same focus they did as private entities. While resources might increase, I’d say the bureaucratic disadvantage is greater. These acquisitions improve Nordhealth’s chances. And there aren’t really any other true competitors. Acquisitions. Will future growth rely too heavily on acquisitions? They recently paid 400 million for Aspit, which is about 6x revenue. Doesn’t sound cheap. Cara reportedly dropped out of the bidding at 200 million. The higher the multiples, the greater the risk that acquisitions won’t achieve the targeted returns.  Biggest pros:  High net retention, like Cara. Indicates that there are generally many cross-selling opportunities in the industry. The industry is growing. Strong position in the Nordic countries. Limited competition. Expansion into more markets in the veterinary sector is much easier than for Cara due to regulation. From my understanding, management seems competent. A clear strategy of acquiring legacy systems, converting them to SaaS, and increasing average customer billing by selling additional modules/services.

Let’s open a thread for this newly listed, interesting company. Nordhealth AS [NORDH], listed on Norway’s Euronext Growth this week, is a Finnish-born company focused on cloud-based healthcare, grown through acquisitions and organically. Its business is to modernize clients’ legacy systems with its own SaaS-based products. The company offers various patient information systems for veterinarians and therapists from different fields, and according to the company, its clients include IVC Evidensia, AniCura, Coronaria, and Fysios. Revenue in 2020 was approximately 20 million euros, and at the end of Q1/21, annual recurring revenue (ARR) was approximately 21.4 million euros. According to management’s forecast, ARR is expected to grow to 23-25 million euros by the end of 2021. As far as I understand, about 85% of the revenue is recurring. Calculated with pro-forma figures, revenue has grown 15-17% annually in the 2018-2020 period. Gross margin appears to be over 80% in the same period. The funds raised from the IPO are intended to be used to accelerate growth through acquisitions and product development. The company was listed last week with a market capitalization of 320 million euros, which can be considered relatively high based on the 15 P/S ratio derived from the last fiscal year, but reasonable if management’s forecasts (>110M ARR in the next 4-5 years) are realized. Company presentation from the company’s website: https://nordhealth.com/assets/attachments/nordhealth-as-group-presentation.pdf I believe the company has potential, but global expansion, especially with a focus on acquisitions, increases the risk profile. I do not have information about the quality of the company’s products, but a 119% average net retention rate certainly tells something.

NordHealth

Helsinki, Finland, 31 March 2026: A maximum of 7,217,260 performance-based options linked to the Company's shares under an incentive scheme (the "Options"), were granted to members of the Company...

Helsinki, Finland, 31 March 2026: A maximum of 7,217,260 performance-based options linked to the Company's shares under an incentive scheme (the "Options"), were granted to members of the Company's executive management and key employees, on 30 September 2025.The board of Nordhealth AS (the "Company") has today approved to amend the strike price of all 7,217,260 of the granted options, from NOK 35.20 to NOK 30.00, under the following conditions:<ul>	<li aria-level="1">The start of the time-based vesting of the Options is reset to 31st March 2026, and the Options still vest quarterly over 4 years.</li>	<li aria-level="1">The price-based performance thresholds remain unchanged (no Options vest below 11% CAGR in the share price, with linear increase up to 25% CAGR).</li>	<li aria-level="1">New condition: No Options vest below a minimum threshold of NOK 40.00 share price.</li>	<li aria-level="1">No increases have been or will be made to participants' salaries or bonuses in 2026.</li>	<li aria-level="1">The Option agreement remains the same in all other conditions.</li></ul>For further information, please contact:Charles MacBain, CEO charles.macbain@nordhealth.comAlexander Cram, CFO alexander.cram@nordhealth.com<div></div>

Nordhealth Oy: Nordhealth AS: Amendment of performance-based options to executive management and key employees

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation